GM03 - Platelet RNA Signatures of Aspirin

Aspirin Clinical Trial

Official title:

DEVELOPMENT OF PROGNOSTIC PLATELET RNA BIOMARKERS TO TAILOR ANTIPLATELET THERAPY

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05278637
• Other study ID #: Pro00048621
• Status: Completed
• Phase: Early Phase 1
• Start date: November 1, 2013
• Est. completion date: December 5, 2016

Study information

• Verified date: March 2022
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.

Description:

Protocol A This will be a randomized, cross-over design comparing low- and high-dose aspirin as well as a non-aspirin platelet inhibitor ticagrelor. This antiplatelet exposure study will be conducted at the DCRU using two separate cohorts: 1) healthy adult volunteers 2) patients with Type 2 diabetes. Subjects within each cohort will but in general will have platelet function testing and biospecimen collection before, four weeks, and eight weeks after low- or high-dose aspirin exposure. Subsequently there will be a period of aspirin washout and a four-week exposure to ticagrelor, a non-aspirin platelet inhibitor. In all subjects and at various time points peripheral blood RNA, purified platelets, DNA, serum, fecal samples and/or plasma will be collected.

Protocol B This will be a single arm study of the platelet inhibitor ticagrelor that is essentially the last two visits of Protocol A. This study will be conducted at the DCRU and will only be open to healthy adult volunteers and patients with Type 2 diabetes. Subjects who elect to participate in this protocol will follow the protocol outlined in Figure 2 and in general will have platelet function testing and biospecimen collection before and four weeks after exposure to ticagrelor, a non-aspirin platelet inhibitor. In all subjects and at various time points (see Figure 2 and Table 2) peripheral blood RNA, purified platelets, DNA, serum, and/ plasma will be collected. In order to align the visits with that of Protocol A, the two visits under this protocol will be labelled V4 and V5.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 135
• Est. completion date: December 5, 2016
• Est. primary completion date: December 5, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 75 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers

• Age = 30 and = 75

• Non-smoker

• The total number of enrolled females should not exceed 55% of the entire cohort. Therefore, the PI may include/exclude individuals on the basis of gender to achieve an equal balance between men and women.

Exclusion Criteria:

• History of bleeding disorder, gastrointestinal bleeding, intracranial bleeding or known prior gastric ulcer without documented resolution

• Current regular use of antiplatelet agents (aspirin, cilostazol, prasugrel, clopidogrel, dipyridamole, ticagrelor, or ticlopidine), nonsteroidal anti-inflammatory agents (NSAIDs), oral corticosteroids (i.e. prednisone), anticoagulants (warfarin, dabigatran, apixaban, rivaroxaban, enoxaparin)

• Known, severe hepatic impairment

• Surgery within the last 6 months, at the discretion of the PI

• Prior gastric bypass surgery (or equivalent) that interferes with absorbption at the discretion of the PI

• Aspirin allergy or known intolerance to aspirin or ticagrelor.

• Comorbid conditions:

1. hypertension (requiring prescription medication).

2. hyperlipidemia (requiring medications)

3. Type 1 or 2 Diabetes

Related Conditions & MeSH terms

• Aspirin
• Platelet Aggregation Inhibitors
• Ticagrelor

Intervention

Drug:
• Aspirin
Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.
• Ticagrelor
Ticagrelor 90mg BID x 4 weeks

Locations

Country	Name	City	State
United States	Duke University	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in expression levels of platelet messenger RNA		Baseline, after every 4 week exposure
Secondary	Change in platelet function score		Baseline, 3 hours, after every 4 week exposure